Sandoz Strengthens Immunology Portfolio with Samsung Bioepis Deal to Commercialize Biosimilar Ustekinumab
The partnership with Samsung Bioepis Grants Novartis’ generic-drugs unit Sandoz exclusive commercialization rights for biosimilar SB17 Ustekinumab in Europe and
Read more